Alzheimer’s drug targeting soluble amyloid falls short in a large clinical trial

A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline. Columbia University Irving Medical Center (CUIMC) led the multicenter study. Researchers have proposed that Alzheimer’s disease is caused by the […]

Science Blog http://ift.tt/2DEebrk



http://ift.tt/2E8w1Qf
Visit our website to read more

Kommentit

Tämän blogin suosituimmat tekstit

Jack the ripper අභිරහස් ඝාතකයා